• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Catheters
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Injection Molding
    • Insert molding
    • Tools
  • Materials
    • Advanced Materials
    • Silicone
  • Research & Development
  • Suppliers

NXgenPort, Mayo Clinic ink license agreement over chemo-port catheter for home monitoring

May 11, 2021 By Danielle Kirsh

nxgenport-mayoclinicNXgenPort today announced that it has entered into a license agreement with Mayo Clinic to develop and test an implantable chemo-port catheter.

NXgenPort’s technology has chemo-port efficacy with sensor technology to measure and remotely monitor the early onset of complications by reporting and tracking patient response during treatment.

“NXgenPort will bring the benefits of remote patient monitoring to cancer patients, who may have limited support between their treatments. Advances in sensor technology are enabling better patient management in diabetes and heart function care – it is time for cancer patients to benefit as well,” NXgenPort chief sciences officer Rosanne Welcher said in a news release.

The implantable chemo-port catheter uses microelectronic sensors that remotely monitor patients and report physiological body functions over the course of cancer treatment.

Under the agreement, Mayo Clinic’s center for digital health medical director and breast oncologist Tufia Haddad will advise NXgenPort.

“Support Dr. Haddad and Mayo Clinic will be invaluable in this critical stage of prototype development. So often, companies can waste money and time building products that do not fit within the workflow of clinicians or within the needs of organizations. Having early input from Dr. Haddad will help us build a product from the beginning that has value, scalability and increased potential for adoption,” NXgenPort cofounder Cathy Skinner said.

Filed Under: Catheters Tagged With: Mayo Clinic, NXgenPort

Primary Sidebar

DeviceTalks Tuesdays

DeviceTalks Tuesdays
MDO ad

Stay Current

Need Medical Tubing news in a minute?
We Deliver!

Medical Tubing + Extrusion newsletter get you caught up on all the mission critical news you need in medical tubing. Sign up today.

Enews Sign up

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

Medical Tubing & Extrusion

Subscribe to our e-newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS